Citations

Clear

116 citation(s) found for "Davis, Mark".

Long‐term risk of death in patients with hidradenitis suppurativa
Kohorst, John J. , Ghanavatian, Shirin, Davis, Mark D.P. , Weaver, Amy L. , Schleck, Cathy D. , Swanson, David C. , Swanson, David L

Mayo Clinic

International Journal of Dermatology | September 13, 2022 | Volume: 62 | Issue: 5 | Pages: 631-636

10.1111/ijd.16409 | PMID 36097962 Get It

Abstract Background Hidradenitis suppurativa (HS) is associated with substantial morbidity. Few studies have addressed the natural history and mortality rates associated with HS. A higher risk of cardiovascular death in patients with HS has been reported. We investigated whether patients with HS have an increased overall risk of death compared with age‐ and gender‐matched referents. Methods We performed a retrospective cohort study of residents of Olmsted County, Minnesota, with incident HS between January 1, 1980, and December 31, 2008, and age‐ and gender‐matched referents. The main outcomes and measures were the overall and cause‐specific risks of death. Results We identified 226 incident cases of HS and 678 age‐ and gender‐matched referents among Olmsted County residents during the study period. Compared to referents, patients with HS had a significantly higher risk of all‐cause death (hazard ratio [HR, 2.48; 95% CI, 1.53–4.03, P < 0.001) and cardiovascular‐ or cerebrovascular‐related death (HR, 2.85; 95% CI, 1.10–7.40, P = 0.03). However, these risks were attenuated by adjusting for smoking history: all‐cause HR, 1.65 (95% CI, 0.97–2.82, P = 0.07) and cardiovascular‐ or cerebrovascular‐related HR, 2.03 (95% CI, 0.71–5.81, P = 0.18). The 71% of patients were former or current smokers at the time of HS diagnosis. Conclusions Hidradenitis suppurativa patients have a substantially increased risk of death from any cause, including cardiovascular or cerebrovascular causes; the risk is especially dependent on smoking history.
Differential proteomic expression in indolent vulvar lichen sclerosus, transforming vulvar lichen sclerosus and normal vulvar tissue
Gleue, Casey A. , Xie, Fangyi , Deschaine, Maria , Dasari, Surendra , Sartori‐Valinotti, Julio C. , Torgerson, Rochelle R. , Davis, Mark D. P. , Charlesworth, M. Cristine , Meves, Alexander , Lehman, Julia S. , Lehman, Julia S , Davis, Mark D.P. , Charlesworth, M. Cristine

Mayo Clinic

Experimental Dermatology | August 12, 2022 | Volume: 31 | Issue: 12 | Pages: 1920-1926

10.1111/exd.14660 | PMID 35960231 Get It

AbstractVulvar lichen sclerosus (VLS) confers approximately 3% risk of malignant transformation to vulvar squamous cell carcinoma (VSCC). We used unbiased proteomic methods to identify differentially expressed proteins in tissue of patients with VLS who developed VSCC compared to those who did not. We used laser capture microdissection‐ and nanoLC‐tandem mass spectrometry to assess protein expression in individuals in normal vulvar tissue (NVT, n = 4), indolent VLS (no VSCC after at least 5 years follow‐up, n = 5) or transforming VSCC (preceding VSCC, n = 5). Interferon‐γ and antigen‐presenting pathways are overexpressed in indolent and transforming VLS compared to NVT. There was differential expression of malignancy‐related proteins in transforming VLS compared to indolent VLS (CAV1 overexpression, AKAP12 underexpression), particularly in the EIF2 translation pathway, which has been previously implicated in carcinogenesis. Results of this study provide additional molecular evidence supporting the concept that VLS is a risk factor for VSCC and highlights possible future biomarkers and/or therapeutic targets.
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)
Khan, Seema A. , Zhao, Fengmin, Goldstein, Lori J. , Cella, David , Basik, Mark , Golshan, Mehra, Julian, Thomas B., Pockaj, Barbara A., Lee, Christine A. , Razaq, Wajeeha, Babiera, Gildy V., Dy, Irene A., Jain, Sarika, Silverman, Paula , Fisher, Carla S., Sparano, Joseph A , Silverman, Paula , Tevaarwerk, Amye J , Wagner, Lynne , Sledge, George W , Khan, Seema A. , Zhao, Fengmin, Goldstein, Lori J. , Cella, David , Basik, Mark , Golshan, Mehra, Julian, Thomas B., Pockaj, Barbara A., Lee, Christine A. , Razaq, Wajeeha, Babiera, Gildy V., Dy, Irene A., Jain, Sarika, Fisher, Carla S.

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 9 | Pages: 978-987

10.1200/jco.21.02006 | PMID 34995128 Get It

PURPOSE Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results. METHODS Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8 months; if no disease progression occurred, they were randomly assigned to locoregional therapy for the primary site (surgery and radiotherapy per standards for nonmetastatic disease) or continuing sysmetic therapy. The primary end point was OS; locoregional control and quality of life were secondary end points. The trial design provided 85% power to detect a 19.3% absolute difference in the 3-year OS rate in randomly assigned patients. The stratified log-rank test and Cox proportional hazards model were used to compare OS between arms. Cumulative incidence of locoregional progression was compared using Gray's test. Quality-of-life assessment used standard instruments. RESULTS Of 390 participants enrolled, 256 were randomly assigned: 131 to continued systemic therapy and 125 to early locoregional therapy. The 3-year OS was 67.9% without and 68.4% with early locoregional therapy (hazard ratio = 1.11; 90% CI, 0.82 to 1.52; P = .57). The median OS was 53.1 months (95% CI, 47.9 to not estimable) in the systemic therapy arm and 54.9 months (95% CI, 46.7 to not estimable) in the locoregional therapy arm. Locoregional progression was less frequent in those randomly assigned to locoregional therapy (3-year rate: 16.3% v 39.8%; P < .001). Quality-of-life measures were largely similar between arms. CONCLUSION Early locoregional therapy for the primary site did not improve survival in patients presenting with metastatic breast cancer. Although it was associated with improved locoregional control, this had no overall impact on quality of life.
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Pose, Elisa , Solà, Elsa , Lozano, Juan José , Juanola, Adrià , Zaccherini, Giacomo , Wit, Koos de , Tonon, Marta , Kazankov, Konstantin , Jiménez, César , Campion, Daniela , Napoleone, Laura , T., Ann , Carol, Marta, Alessandria, Carlo , Beuers, Ulrich , Caraceni, Paolo , Trebicka, Jonel , Vargas, Vı́ctor , Abraldeṣ, Juan G. , Kamath, Patrick S. , Davis, Mark M. , Cervera, Marta , Solé, Cristina , Graupera, Isabel , Serra‐Burriel, Miquel , Gratacós‐Ginès, Jordi , Bassegoda, Octavi , Roux, Olivier , de Wit, Koos , Trebicka, Jonel , Piano, Salvatore , Gines, Pere , Ma, Ann T , Vargas, Victor , Jiménez, César , Abraldes, Juan G , Sidorova, Julia , Uschner, Frank Erhard , Morales‐Ruiz, Manuel , Francoz, Claire , Durand, François , Mookerjee, Rajeshwar P. , Piano, Salvatore , Watson, Hugh R , Ginès, Pere

Mayo Clinic

Hepatology Communications | December 29, 2021 | Volume: 6 | Issue: 5 | Pages: 1100-1112

10.1002/hep4.1881 | PMID 34964311 Get It

Patients with decompensated cirrhosis, particularly those with acute‐on‐chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE‐SAFETY randomized, double‐blind, placebo‐controlled trial treated with simvastatin 20 mg/day plus rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography–tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and lipid alterations, specifically in pathways associated with inflammation and mitochondrial dysfunction, such as the tryptophan–kynurenine and carnitine beta‐oxidation pathways. An ACLF‐specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the tryptophan–kynurenine and carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with simvastatin and rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with simvastatin and rifaximin in decompensated cirrhosis and sets the stage for the use of metabolomics to investigate new targeted therapies in cirrhosis to prevent ACLF development.
Development of pemphigus vulgaris after the second dose of the mRNA‐1273 SARS‐Cov‐2 vaccine
Koutlas, Ioannis G. , Camara, Renee, Davis, Mark D.P. , Miller, Daniel D. , Davis, Mark Denis P., Argyris, Prokopios P.

Mayo Clinic

Oral Diseases | November 26, 2021 | Volume: 28 | Issue: S2 | Pages: 2612-2613

10.1111/odi.14089 | PMID 34825752 Get It

Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta‐analysis
Hanna, Nardin , Silverberg, Orli M. , Reaume, Michael , Davis, Mark D.P. , Piguet, Vincent , Piguet, V , Gladman, Dafna D. , Alavi, Afsáneh

Mayo Clinic

International Journal of Dermatology | August 25, 2021 | Volume: 61 | Issue: 9 | Pages: 1069-1079

10.1111/ijd.15860 | PMID 34432308 Get It

AbstractAn increasing amount of evidence has emerged suggesting that hidradenitis suppurativa (HS) is associated with inflammatory arthritis. This study reviewed the incidence, prevalence, and predictors of inflammatory arthritis in patients with HS. A comprehensive literature search was conducted in CINAHL, Embase, and Medline from inception to February 14, 2020. Articles were included in the review if they provided data on disease epidemiology or predictors of adult or pediatric HS patients with comorbid inflammatory arthritis. There are no validated diagnostic criteria for HS, thus we considered patients as having HS if they had at least one diagnostic code in a hospital or claims database or a diagnosis of HS/inflammatory arthritis in a medical record. The same criteria were used to confirm presence of inflammatory arthritis. We identified an increased incidence of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) in HS patients when compared with estimates in the general population. We identified a relatively high prevalence of RA, spondyloarthritis (SpA), and PsA in HS patients when compared with estimates in the general population. There was evidence to suggest that patients who are younger than 30, male, have severe HS, or are taking infliximab or adalimumab (which may also be confounded by HS disease severity) may be at greater risk for specific subtypes of inflammatory arthritis. However, further data are needed to confirm these associations. The increased incidence and prevalence of inflammatory arthritis within HS patients underscore the need for increased awareness and interdisciplinary partnership within rheumatology and dermatology.
Retrospective analysis of 450 emergency department dermatology consultations: An analysis of in-person and teledermatology consultations from 2015 to 2019
Hines, Alexander , Zayas, Jacqueline , Wetter, David A. , Bridges, Alina G. , Camilleri, Michael , McEvoy, Marian T., Goyal, Deepi G. , Davis, Mark D. P. , Sartori‐Valinotti, Julio C. , Hines, Alexander S , El-Azhary, Rokea A, Davis, Mark DP., Sartori-Valinotti, Julio C., el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

Journal of Telemedicine and Telecare | June 18, 2021 | Volume: 29 | Issue: 10 | Pages: 808-815

10.1177/1357633x211024844 | PMID 34143696 Get It

Introduction Dermatologic complaints are a common reason for emergency department visits. Methods Retrospective chart review from 1 January 2015 to 31 December 2019. Patients in the Mayo Clinic Emergency Department receiving dermatology consultation were included. Results Dermatitis (24.7%, n = 113), infection (20.4%, n = 93), and drug reaction (10.3%, n = 47) accounted for the majority of diagnoses. Emergency department providers often provide no diagnosis (38%) or a differential diagnosis (22%), and dermatology consultation frequently alters diagnosis (46%) and treatment (83%). Patients receiving in-person consultations are admitted more frequently than those receiving teledermatology consultations (40% vs. 16%, p < 0.001). Primary diagnostic concordance with subsequent dermatology evaluation is high for in-person (94%) and teledermatology (88%) consultations. Discussion This is the largest study of emergency department dermatology consultations in the United States and the first to compare in-person and teledermatology emergency department consultation utilization in clinical practice. These modalities are utilized in a complementary fashion at our institution, with severe dermatologic diagnoses seen in-person. The valuable role of emergency department dermatologists is highlighted by frequent changes to diagnosis and treatment plans that result from dermatology consultation. Furthermore, our data suggest that teledermatology is an effective modality with the potential to expand access to dermatologic expertise in the emergency department setting.
Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates
Shamim, Huma, Davis, Mark D.P., Wetter, David A. , Newman, Catherine C., Comfere, Nneka I. , Sokumbi, Olayemi

Mayo Clinic

The American Journal of Dermatopathology | June 16, 2021 | Volume: 43 | Issue: 10 | Pages: 714-720

10.1097/dad.0000000000001875 | PMID 34132660 Get It

Background: Observations highlighting the “unmasking” of cutaneous T-cell lymphoma after treatment with dupilumab for atopic dermatitis (AD) have been recently reported. However, there remains a paucity of literature describing the evolution of clinical and histopathological features that characterizes this phenomenon. Objective: To define the clinical and histopathologic evolution of atypical lymphoid infiltrates after the administration of dupilumab for AD. Methods: A cross-sectional study of clinical and histopathologic features in 7 consecutive patients with a diagnosis of “atypical lymphoid infiltrate” or mycosis fungoides (MF) on dupilumab for AD was performed. Results: Seven patients with atypical lymphoid infiltrates or MF in evolution after dupilumab therapy (age range 27–74 years) were reviewed. Average duration of AD before MF diagnosis was 5.7 years, and the average duration on dupilumab treatment was 9.8 months. Notable histopathologic features across predupilumab and postdupilumab biopsies included progressive increase in the densities of the atypical lymphoid infiltrates (7/7), presence of atypical epidermotropic lymphocytes (6/7), and papillary dermal fibrosis (6/7). Limitations: Small retrospective cohort study. Conclusion: These cases highlight the transformation of lymphoid infiltrates after dupilumab treatment for AD and emphasize the importance of clinical and histopathologic evaluation before and during treatment with dupilumab for treatment-refractory presumed AD.
Retrospective analysis of 578 inpatient dermatology consultations in hematology and hematopoietic stem cell transplant patients
Hines, Alexander , Wetter, David A. , Bridges, Alina G. , Camilleri, Michael , McEvoy, Marian T., Davis, Mark D. P. , Sartori‐Valinotti, Julio C. , Hazim, Antonious , El-Azhary, Rokea A, Sartori-Valinotti, Julio C., Hines, Alexander S , el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

International Journal of Dermatology | May 15, 2021 | Volume: 60 | Issue: 11 | Pages: 1385-1391

10.1111/ijd.15650 | PMID 33991106 Get It

AbstractBackgroundHospitalized patients with hematologic malignancies are medically complex and commonly affected by dermatologic conditions.MethodsRetrospective chart review from January 1, 2014, to December 31, 2018, at Rochester Methodist Hospital (Rochester, Minnesota, USA). Patients hospitalized on hematology and BMT services receiving dermatology consultation were included.ResultsIn all, 578 consultations (63% male, median age 61 years) were reviewed. Drug reactions (22%), infection (17%), and malignant neoplasm (10%) accounted for nearly half of diagnoses. Exanthematous drug reaction (10%), graft‐versus‐host disease (7%), and lymphoma or leukemia cutis (6%) were the commonest individual diagnoses. There were significantly more drug reactions in severe neutropenia (33.2% vs. 15.0%), neutrophilic dermatoses in myeloid neoplasm (5.2% vs. 0.3%), and viral infection in lymphoid neoplasm (8.3% vs. 1.2%). Consultation frequently altered treatment (68%), diagnostic workup (63%), and the primary service’s initial diagnostic impression (53%). Biopsies were performed in 52% of consultations and helped secure a diagnosis 73% of the time. A total of 16.4% of consultations did not receive a definitive final diagnosis, and 18.5% were resolved in one visit.ConclusionThis is the largest study to date of hospital dermatology consultation in hematology patients. Biopsies are utilized frequently and are diagnostically useful. The complexity of this patient population is evidenced by the fact that a final diagnosis remains elusive in a number of cases despite the multiple visits required for the vast majority of consultations. Nevertheless, dermatology consultation alters diagnosis and treatment in the majority of patients, highlighting the critical role dermatologists have in the care of these patients.